한국인 전이성 및 거세저항성전립선암 환자의 치료
The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea
하윤수, 하유신, 정진우, 박봉희, 김형준, 김기홍, 여정균,
소속 상세정보
하윤수 ( Ha Yoon-Soo )
대구가톨릭대학교 의과대학 비뇨기과학교실
하유신 ( Ha U-Syn )
가톨릭대학교 서울성모병원 비뇨기과
정진우 ( Jung Jin-Woo )
가톨릭관동대학교 의과대학 국제성모병원 비뇨기과
박봉희 ( Park Bong-Hee )
가톨릭대학교 의과대학 의정부성모병원 비뇨기과
김형준 ( Kim Hyung-Joon )
건양대학교 의과대학 비뇨기과학교실
김기홍 ( Kim Ki-Hong )
순천향대학교 의과대학 비뇨기과학교실
여정균 ( Yeo Jeong-Kyun )
인제대학교 서울백병원 비뇨기과
Abstract
The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines.
키워드
Prostatic neoplasms; Castration-resistant; Korea
원문 및 링크아웃 정보
등재저널 정보